GlassScriptPhysician profile
John B Chastain
NPI 1801915715
$4,382.12
in general payments reported to CMS, 2019-2025
22 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 90% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $206 · 2021: $165 · 2022: $781 · 2023: $298 · 2024: $372 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Travel and Lodging: $1,116 · Consulting Fee: $100 · Education: $91.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.63 |
| Travel and Lodging | $1,116.48 |
| Consulting Fee | $100.00 |
| Education | $91.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,074.13 | 2019-2025 | |
| Stryker Corporation | $649.17 | 2019-2025 | Latera, Scopis Ent |
| Genzyme Corporation | $420.72 | 2020-2025 | |
| Glaxosmithkline, LLC. | $291.29 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $209.94 | 2022-2025 | Dupixent |
| Optinose US, INC. | $173.08 | 2019-2022 | |
| Medtronic, INC. | $112.71 | 2022-2023 | Straightshot |
| Astrazeneca Pharmaceuticals LP | $84.05 | 2019 | |
| Carestream Dental, LLC | $62.44 | 2019 | |
| Amgen INC. | $46.97 | 2022-2025 | Tezspire |
| Kaleo, INC. | $38.12 | 2020 | |
| Davol INC. | $33.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.83 | 2021 | |
| Merck Sharp & Dohme LLC | $22.69 | 2025 | Keytruda |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $20.68 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Getinge USA Sales, LLC | $16.39 | 2025 | Ultima Activator II Drive Mechanism |
| Acclarent, INC | $16.32 | 2019 | |
| Integra Lifesciences Corporation | $15.22 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boston Scientific Corporation | $12.84 | 2019 | |
| Intersect Ent, INC. | $12.57 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chastain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.